GlassScriptPhysician profile
Samuel M Einbinder
NPI 1144725466
$2,080.84
in general payments reported to CMS, 2019-2025
12 companies · $2,026 in 2025
The $2,026 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $54.40 · 2025: $2,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,081.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,080.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $801.34 | 2025 | Apretude, Cabenuva |
| Gilead Sciences, INC. | $349.07 | 2025 | Yeztugo |
| Amgen INC. | $300.98 | 2025 | Tepezza, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $247.05 | 2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $182.24 | 2025 | Caplyta |
| Ucb, INC. | $42.86 | 2025 | Bimzelx |
| Fidia Pharma USA INC. | $39.77 | 2024 | Triluron, Hymovis, Hyalgan |
| Janssen Biotech, INC. | $32.88 | 2025 | Talvey, Darzalex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.94 | 2025 | Xifaxan |
| Glaxosmithkline, LLC. | $22.86 | 2025 | Benlysta |
| Exact Sciences Corporation | $22.22 | 2025 | Cologuard Collection Kit |
| Novo Nordisk INC | $14.63 | 2024 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Einbinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.